Purpose: For anaplastic lymphoma kinase (ALK) gene detection, the centrifugal sedimentation method (CSM) and cell block method (CBM) are commonly used to process samples of bloody pleural effusions (BPEs). However, in practice, the impurity content in the processed samples often affects the results and even leads to the detection failure. The purpose of this study was to establish a cell enrichment method (CEM) by using a disposable membrane cell collector to remove blood and inflammatory cells and enrich lung adenocarcinoma cells in BPE for more efficient RNA extraction and ALK gene detection. Materials and Methods: CEM proposed in this study and the traditional CSM and CBM were used to treat BPE samples collected from 37 lung adenocarcinoma patients. A DeNovix DS-11 ultraviolet spectrophotometer was used to measure the concentration and purity of extracted RNA. Amplification refractory mutation systems (ARMS) and ABI 7500 fluorescence qPCR were used to detect ALK gene. Through statistical analysis, the CEM was compared with the CSM and CBM in RNA concentration, purity, and ALK gene detection results. Results: The concentration of RNA extracted by using the CEM was significantly higher than that extracted by using the CBM and CSM (p < 0.001). The purity of RNA extracted by using the CEM was significantly higher than that by the other 2 methods (p = 0.011, p = 0.005). ALK gene testing with PCR was successful in all the samples using the CEM, but 2 cases by the CSM and 1 case by the CBM failed. Conclusions: Using the disposable membrane cell collector to process BPE of lung adenocarcinoma patients for RNA extraction and ALK gene detection is more effective and successful compared with the traditional methods, and it is suggested to be further applied and popularized in clinical practice.

1.
Ettinger
DS
,
Wood
DE
,
Aggarwal
C
,
Aisner
DL
,
Akerley
W
,
Bauman
JR
, et al
NCCN guidelines insights: non-small cell lung cancer, version 1.2020
.
J Natl Compr Canc Netw
.
2019
;
17
(
12
):
1464
72
. .
2.
Thomas
R
,
Roy
B
,
Maldonado
F
,
Lee
YCG
.
Management of Malignant pleural effusions-what is new
.
Semin Respir Crit Care Med
.
2019
;
40
(
3
):
323
39
. .
3.
Tian
T
,
Zhang
P
,
Zhong
F
,
Sun
C
,
Zhou
J
,
Hu
W
.
Nomogram construction for predicting survival of patients with non-small cell lung cancer with malignant pleural or pericardial effusion based on SEER analysis of 10,268 patients
.
Oncol Lett
.
2020
;
19
(
1
):
449
59
.
4.
Zhang
X
,
Zhao
Y
,
Wang
M
,
Yap
WS
,
Chang
AY
.
Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer
.
Lung Cancer
.
2008
;
60
(
2
):
175
82
. .
5.
Dubey
AP
,
Pathi
N
,
Viswanath
S
,
Rathore
A
,
Pathak
A
,
Sud
R
.
New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer
.
Indian J Cancer
.
2017 Jan–Mar
;
54
(
1
):
203
8
. .
6.
Zhuang
X
,
Zhao
C
,
Li
J
,
Su
C
,
Chen
X
,
Ren
S
, et al
Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
.
Cancer Med
.
2019
;
8
(
6
):
2858
66
. .
7.
Liu
J
,
Mu
Z
,
Liu
L
,
Li
K
,
Jiang
R
,
Chen
P
, et al
Frequency, clinical features and differential response to therapy of concurrent ALK/EGFR alterations in Chinese lung cancer patients
.
Drug Des Devel Ther
.
2019
;
13
:
1809
17
. .
8.
Wang
Z
,
Zhang
X
,
Bai
H
,
Zhao
J
,
Zhuo
M
,
An
T
, et al
EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer
.
Oncology
.
2012
;
83
(
5
):
248
56
. .
9.
Zhong
S
,
Zhang
HP
,
Zheng
J
,
Bai
DY
,
Fu
L
,
Chen
PQ
.
[Detection of EML4-ALK fusion gene in non-small cell lung cancer and its clinicopathologic correlation]
.
Zhonghua Bing Li Xue Za Zhi
.
2013
;
42
(
4
):
252
6
. .
10.
Tian
P
,
Liu
Y
,
Zeng
H
,
Tang
Y
,
Lizaso
A
,
Ye
J
, et al
Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes
.
J Cancer Res Clin Oncol
.
2020
;
146
(
4
):
935
44
. .
11.
Zhu
X
,
Li
H
,
Cao
B
,
Liu
C
,
Liang
L
,
Wang
Y
, et al
[The research of clinical pathological features of ALK positive lung cancer in 525 patients and the discussion of detection methods]
.
Zhongguo Fei Ai Za Zhi
.
2014
;
17
(
3
):
226
32
. .
12.
Solomon
BJ
,
Mok
T
,
Kim
DW
,
Wu
YL
,
Nakagawa
K
,
Mekhail
T
, et al
First-line crizotinib versus chemotherapy in ALK-positive lung cancer
.
N Engl J Med
.
2014
;
371
(
23
):
2167
77
. .
13.
Solomon
BJ
,
Cappuzzo
F
,
Felip
E
,
Blackhall
FH
,
Costa
DB
,
Kim
DW
, et al
Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014
.
J Clin Oncol
.
2016
;
34
(
24
):
2858
65
. .
14.
Solomon
BJ
,
Kim
DW
,
Wu
YL
,
Nakagawa
K
,
Mekhail
T
,
Felip
E
, et al
Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer
.
J Clin Oncol
.
2018
;
36
(
22
):
2251
8
. .
15.
Demidova
I
,
Barinov
A
,
Savelov
N
,
Gagarin
I
,
Grinevitch
V
,
Stroiakovaski
D
, et al
Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls
.
Arch Pathol Lab Med
.
2014
;
138
(
6
):
794
802
. .
16.
Li
T
,
Maus
MK
,
Desai
SJ
,
Beckett
LA
,
Stephens
C
,
Huang
E
, et al
Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays
.
J Thorac Oncol
.
2014
;
9
(
1
):
18
25
. .
17.
Wallander
ML
,
Geiersbach
KB
,
Tripp
SR
,
Layfield
LJ
.
Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing
.
Arch Pathol Lab Med
.
2012
;
136
(
7
):
796
803
. .
18.
Wu
G
,
Zhou
C
,
Bai
C
,
Qian
G
.
Chinese expert consensus on molecularly targeted therapy for advanced non-small cell lung cancer (2013 edition)
.
J Thorac Dis
.
2014
;
6
(
10
):
1489
98
. .
19.
Zhang
X
,
Lu
S
,
Zhang
L
.
Guideline for diagnosis and treatment of non-small cell lung cancer patients with epidermal growth factor receptor mutation or anaplastic lymphoma kinase rearrangement (2013): oncology branch of Chinese Medical Doctor Association Chemotherapy Committee of Chinese Anti-cancer Association
.
Chin J Oncol
.
2013
;
35
:
478
9
.
20.
Wang
Y
,
Zhang
J
,
Gao
G
,
Li
X
,
Zhao
C
,
He
Y
, et al
EML4-ALK fusion detected by RT-PCR confers similar response to crizotinib as detected by FISH in patients with advanced non-small-cell lung cancer
.
J Thorac Oncol
.
2015
;
10
(
11
):
1546
52
. .
21.
Shah
SG
,
Rashid
M
,
Verma
T
,
Ludbe
M
,
Khade
B
,
Gera
PB
, et al
Establishing a correlation between RIN and A260/280 along with the multivariate evaluation of factors affecting the quality of RNA in cryopreserved cancer bio-specimen
.
Cell Tissue Bank
.
2019
;
20
(
4
):
489
99
. .
22.
Strand
C
,
Enell
J
,
Hedenfalk
I
,
Fernö
M
.
RNA quality in frozen breast cancer samples and the influence on gene expression analysis: a comparison of three evaluation methods using microcapillary electrophoresis traces
.
BMC Mol Biol
.
2007
;
8
:
38
. .
23.
Fleige
S
,
Pfaffl
MW
.
RNA integrity and the effect on the real-time qRT-PCR performance
.
Mol Aspects Med
.
2006
;
27
(
2–3
):
126
39
. .
24.
Fleige
S
,
Walf
V
,
Huch
S
,
Prgomet
C
,
Sehm
J
,
Pfaffl
MW
.
Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR
.
Biotechnol Lett
.
2006
;
28
(
19
):
1601
13
. .
25.
De Almeida
SM
,
Raboni
SM
,
Nogueira
MB
,
Vidal
LR
.
Red blood cells in cerebrospinal fluid as possible inhibitory factor for enterovirus RT-PCR
.
Arq Neuropsiquiatr
.
2016
;
74
(
10
):
810
5
.
26.
Kubista
M
,
Bjrkman
J
,
Svec
D
,
Sjback
R
.
Rna quality matters
.
Eur Pharm Rev
.
2012
;
17
(
6
):
63
7
.
27.
Fleige
S
,
Walf
V
,
Huch
S
,
Prgomet
C
,
Sehm
J
,
Pfaffl
MW
.
Comparison of relative mRNA quantification models and the impact of RNA integrity in quantitative real-time RT-PCR
.
Biotechnol Lett
.
2006
;
28
(
19
):
1601
13
. .
28.
Micke
P
,
Ohshima
M
,
Tahmasebpoor
S
,
Ren
Z
,
Ostman
A
,
Ponten
F
, et al
Biobanking of fresh frozen tissue : RNA is stable in nonfixed surgical specimens
.
Lab Invest
.
2006
;
86
(
2
):
202
11
.
29.
Ugurluoglu
C
,
Kurtipek
E
,
Unlu
Y
,
Esme
H
,
Duzgun
N
.
Importance of the cell block technique in diagnosing patients with non-small cell carcinoma accompanied by pleural effusion
.
Asian Pac J Cancer Prev
.
2015
;
16
(
7
):
3057
. .
30.
Eichel
HJ
.
Impurity in RNA preparations which inactivates RNase inhibitor and increases alkaline RNase activity
.
Proc Soc Exp Biol Med
.
1962
;
109
(
4
):
804
8
. .
31.
Koch
I
,
Slotta-Huspenina
J
,
Hollweck
R
,
Anastasov
N
,
Hofler
H
,
Quintanilla-Martinez
L
, et al
Real-time quantitative RT-PCR shows variable, assay-dependent sensitivity to formalin fixation: implications for direct comparison of transcript levels in paraffin-embedded tissues
.
Diagn Mol Pathol
.
2006
;
15
(
3
):
149
56
. .
32.
Macabeo-Ong
M
,
Ginzinger
DG
,
Dekker
N
,
McMillan
A
,
Regezi
JA
,
Wong
DT
, et al
Effect of duration of fixation on quantitative reverse transcription polymerase chain reaction analyses
.
Mod Pathol
.
2002
;
15
(
9
):
979
87
. .
33.
Sanchez-Navarro
I
,
Gamez-Pozo
A
,
Gonzalez-Baron
M
,
Pinto-Marin
A
,
Hardisson
D
,
Lopez
R
, et al
Comparison of gene expression profiling by reverse transcription quantitative PCR between fresh frozen and formalin-fixed, paraffin-embedded breast cancer tissues
.
Biotechniques
.
2010
;
48
(
5
):
389
97
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.